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Most simian immunodeficiency viruses use their Nef
protein to antagonize the host restriction factor teth-
erin. A deletion in human tetherin confers Nef resis-
tance, representing a hurdle to successful zoonotic
transmission. HIV-1 group M evolved to utilize the
viral protein U (Vpu) to counteract tetherin. Although
HIV-1 group O has spread epidemically in humans, it
has not evolved a Vpu-based tetherin antagonism.
Herewe show that HIV-1 groupONef targets a region
adjacent to this deletion to inhibit transport of human
tetherin to the cell surface, enhances virion release,
and increases viral resistance to inhibition by inter-
feron-a. The Nef protein of the inferred common
ancestor of group O viruses is also active against
human tetherin. Thus, Nef-mediated antagonism of
human tetherin evolved prior to the spread of HIV-1
group O and likely facilitated secondary virus
transmission. Our results may explain the epidemic
spread of HIV-1 group O.
INTRODUCTION
Human immunodeficiency viruses (HIVs) are the consequence
of numerous zoonotic transmissions of primate lentiviruses to
humans (Sharp and Hahn, 2011). Both HIV-1 and HIV-2 are clas-
sified into multiple groups, each of which arose from an indepen-
dent transmission of a simian immunodeficiency virus (SIV). The
four groups of HIV-1 (M, N, O, and P) originated from SIVs infect-
ing chimpanzees and gorillas, whereas an SIV from sooty man-
gabeys is the direct precursor of at least nine groups of HIV-2.
However, the viruses resulting from these transmissions have
spread with very different efficiency in the human population.
The AIDS pandemic resulted from a single transmission of a
chimpanzee virus (SIVcpz) that led to the emergence of HIV-1
group M strains. In contrast, HIV-1 group N strains, which areCell Host &also of chimpanzee origin, have been detected in fewer than
20 individuals (Delaugerre et al., 2011). The other two groups
of HIV-1 are both more closely related to SIVgor infecting go-
rillas, but again, the two transmissions have had very different
outcomes. HIV-1 group P has only been found in two Cameroo-
nian individuals (Plantier et al., 2009; Vallari et al., 2011), whereas
group O viruses account for 1%–2% of all HIV-1 infections in
Cameroon and neighboring countries in west-central Africa (Ves-
sie`re et al., 2010). Overall it is estimated that HIV-1 group O has
infected about 100,000 individuals (Mourez et al., 2013).
Differences in adaptation to the new human host are likely one
reason for the differential spread of the four groups of HIV-1
(Sauter et al., 2010; Sharp and Hahn, 2011). In particular, the
host restriction factor tetherin seems to represent a significant
obstacle for successful cross-species transmissions of primate
lentiviruses. Tetherin blocks the release of virions from infected
cells (Neil et al., 2008; Van Damme et al., 2008) and thus contrib-
utes to the control of viral replication in vivo (Liberatore and
Bieniasz, 2011). Most SIVs, including the precursors of HIV-1
and HIV-2, encode Nef proteins, which antagonize tetherin in their
respectiveprimatehosts (Jia etal., 2009;Sauteretal., 2009;Zhang
et al., 2009).However, thehuman tetheringenecontainsadeletion
that removes five amino acids from its cytoplasmic domain and
confers resistance to SIV Nef proteins. It is currently believed
that this presents a barrier to successful spread of SIV among hu-
mans, which can only be overcomeby switching fromNef to other
viral antagonists (Sauter et al., 2009; Yang et al., 2010). Indeed,
during adaptation to humans, HIV-1 groupM and (less effectively)
N viruses evolved the ability to utilize another viral protein (Vpu) to
counteract tetherin (Sauter et al., 2009, 2012). However, previous
studies suggested that HIV-1 group O and P viruses failed to
evolve an effective antagonist of human tetherin (Sauter et al.,
2009, 2011; Petit et al., 2011; Vigan and Neil, 2011; Yang et al.,
2011). Thus, it has remained amystery why HIV-1 groupO viruses
have been capable of infecting tens of thousands of people.
To explore this conundrum, we performed functional analyses
of group O Nef proteins, including their inferred most recent
common ancestor (MRCA). In agreement with previous results
(Sauter et al., 2009; Yang et al., 2010, 2011), group O Nefs had
only modest effects on virus release in transient transfectionMicrobe 16, 639–650, November 12, 2014 ª2014 Elsevier Inc. 639
Figure 1. Antitetherin Activity of HIV-1
Group O Nef Proteins
(A) Virus release from 293T cells cotransfected
with an HIV-1 NL4-3 DvpuDnef construct and
vectors expressing the indicated nef alleles or
human (HUM) tetherin. Virus yield was determined
by p24 ELISA (left) or infection of TZM-bl cells
(right). Data show mean percentages (± SEM)
relative to those detected in the absence of teth-
erin (100%) obtained in three independent exper-
iments. The right panel shows the levels of p24
antigen and infectious virus release in the pres-
ence of 100 ng of HUM tetherin expression
construct. For comparison, results obtained for 18
M- and 9 N-Vpus are shown in the bar diagram.
Stars refer to the difference from the EGFP control
panel. *p < 0.05, **p < 0.01, ***p < 0.001.
(B) Effect of HIV-1 Nefs on surface expression of
human tetherin. Shown are the levels of tetherin cell
surface expression in the presence of HIV-1 group
M Vpus or M-, N-, and O-Nefs relative to those
measured in 293T cells transfected with the EGFP
control vector and tetherin expression plasmid
alone (100%). Each symbol represents one indi-
vidual nef or vpu allele. Shown are average values
derived from four to six independent experiments.
(C) PHA-activated PBMCs were transduced with
VSV-G-pseudotyped vpu-defective HIV-1 NL4-3
constructs expressing the indicated nef alleles
and examined for tetherin surface expression
3 days later. Shown are average levels (± SEM) of
surface expression in virally infected (EGFP+) cells
relative to uninfected cells (100%). *** indicates
that O-Nefs are significantly (p < 0.001) more
active than M-, N-, or P-Nefs.
(D) Nef-dependent reduction of HUM and GOR
tetherin surface expression in 293T cells. Shown
are the levels of tetherin cell surface expression in
the presence of various Nefs relative to those
measured in cells transfected with the control
vector expressing only EGFP. The right panel
shows the average levels of HUM and GOR
tetherin surface expression in the presence of
the three SIVgor and HIV-1 O Nefs (see also
Figure S1).
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human tetherin from the cell surface by targeting a region imme-
diately adjacent to the deletion. This tetherin downmodulation
function enhanced virus release from primary CD4+ T cells and
increased viral resistance to inhibition by interferon-a (IFNa).
Notably, the MRCA of group O Nefs was also active against hu-
man tetherin, suggesting that this function was acquired prior to
the spread of contemporary HIV-1 O strains. Our results demon-
strate that the five amino acid deletion in human tetherin does not
confer resistance to primate lentiviral Nef proteins and suggest
that gain of antitetherin activity by Nef facilitated the spread of
HIV-1 group O among humans.
RESULTS
HIV-1 GroupONefs Suppress Cell Surface Expression of
Human Tetherin
Previous studies performed in transfected 293T cells suggested
that HIV-1 group O viruses failed to evolve an effective antago-640 Cell Host & Microbe 16, 639–650, November 12, 2014 ª2014 Elsnist of human tetherin (Sauter et al., 2009; Yang et al., 2011).
We noted, however, that some HIV-1 O Nefs (O-Nefs) increased
virus release slightly in the presence of human tetherin (Sauter
et al., 2009). To examine whether these modest effects were
an indication of antitetherin activity, we tested the effect of eight
contemporary O-Nefs on virus release. All O-Nefs were ex-
pressed at detectable levels (Figure S1A available online) and
exhibited substantially lower potency than the control HIV-1 M
NL4-3 Vpu in the virus release assay (Figure 1A, left). However,
while group M- and N-Nefs were entirely inactive, some
O-Nefs enhanced infectious virus and p24 release above back-
ground in transfected 293T cells (Figure 1A, right).
To determine whether these minor effects on virus release
were associated with Nef-mediated reduction of cell surface
expression of human tetherin, we cotransfected 293T cells
with vectors coexpressing Nef or Vpu and EGFP (or EGFP alone
for control) together with a construct expressing the human teth-
erin ortholog. HIV-1 M Vpus reduced human tetherin cell surface
expression by about 75%, whereas HIV-1 M and N Nefs had noevier Inc.
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sion of each of 15 HIV-1 O Nef proteins clearly reduced cell
surface expression of human tetherin (Figures 1B and S1B).
The only inactive O-Nef was derived from an infectiousmolecular
clone of HIV-1 group O (pCMO2.5) (Tebit et al., 2004), which had
also failed to exhibit antitetherin activity in a previous study (Yang
et al., 2011). Since the CMO2.5 nef allele was also poorly active
in other assays for Nef function (data not shown), we excluded it
from further analyses. Overall, O-Nefs were almost as active as
M-Vpus in downmodulating human tetherin. Since earlier studies
had mainly examined virus release (Sauter et al., 2009; Yang
et al., 2011) or focused only on group O Vpu proteins (Vigan
and Neil, 2011), this group O Nef function has previously gone
unrecognized.
To confirm the effects of O-Nefs on human tetherin in primary
target cells of HIV-1, we cloned several group O nef alleles into
a vpu-defective HIV-1 NL4-3 IRES-EGFP proviral reporter
construct (Schindler et al., 2006). Flow cytometric analyses
showed that HIV-1 group O Nefs decreased cell surface expres-
sion of tetherin substantially in HIV-1-infected human PBMCs,
whereas Nef proteins from HIV-1 group M, N, and P strains
showed only modest effects (Figure 1C). In contrast, the effi-
ciency of Nef-mediated downmodulation of CD4 and MHC-I
was similar in all groups of HIV-1 as well as SIVgor (Figure S1C).
To visualize the effects of Nef on the subcellular localization of
tetherin, we cotransfected 293T cells with constructs expressing
AU1-tagged Nefs or HA-tagged human tetherin and examined
them by laser-scanning confocal microscopy. In the absence
of Nef or in the presence of the group M NL4-3 Nef, tetherin
was localized at the cell surface as well as intracellularly (Figures
S1D and S1E). In contrast, tetherin was detected almost exclu-
sively in intracellular compartments in the presence of the
HJ162 O-Nef (Figure S1F). However, in the presence of the
SIVgor CP2139 Nef, a significant portion of tetherin remained
at the cell surface (Figure S1G). Thus, HIV-1 group O Nefs
evolved the ability to decrease surface levels of tetherin and
sequester it to intracellular perinuclear compartments.
To examine whether O-Nefs specifically adapted to humans,
we analyzed nef alleles from three contemporary SIVgor and
HIV-1 group O strains for their ability to counteract human as
well as gorilla tetherin. Predictably, SIVgor Nefs decreased
surface expression levels of gorilla tetherin more efficiently
than those of human tetherin (Figure 1D). In contrast, HIV-1
group O Nefs were significantly more active against the human
tetherin ortholog (Figure 1D). Thus, HIV-1 O Nefs clearly gained
activity against human tetherin during adaptation to the human
host.
The Nef Protein of the MRCA of HIV-1 Group O
Counteracts Human Tetherin
To assess whether the ability of O-Nefs to suppress cell surface
expression of human tetherin evolved prior to the spread of HIV-
1 groupO in the human population, we inferred the Nef sequence
encoded by the MRCA of group O viruses using maximum-likeli-
hood methods. For comparison, we also inferred the Nef se-
quences of the group M- and N-MRCAs; we synthesized two
M-MRCA Nefs, varying in one residue, to reflect a difference in
the sequences inferred by different reconstruction methods (Fig-
ure S2A). All ancestral Nef proteins were expressed (Figure S2B)Cell Host &and downmodulated CD4 and MHC-I as efficiently as Nefs
from contemporary group M, N, and O strains (Figure S2C).
The O-MRCA Nef significantly increased the release of infec-
tious HIV-1 in 293T cells transfected with different doses of teth-
erin expression plasmids (Figures 2A and S2D). Notably, the
O-MRCA Nef counteracted both human and gorilla tetherin,
whereas SIVgor Nef was only active against the latter, and M-
and N-MRCA Nefs were inactive (Figure 2B). In agreement
with results from virus release assays, M- and N-MRCA Nefs
affected surface expression of human and gorilla tetherin only
marginally, whereas the O-MRCA Nef reduced expression of
both by 70%–80% in transfected 293T cells (Figure 2C), and
of human tetherin by about 70% in HIV-1-infected PBMCs
(Figure 2D).
Recently, it has been shown that tetherin also acts as an im-
mune sensor of HIV-1 that induces NF-kB-dependent proinflam-
matory responses (Gala˜o et al., 2012). To examine possible
effects of O-Nefs on the signaling activity of human tetherin,
we cotransfected 293T cells with a tetherin expression plasmid,
an NF-kB-dependent firefly luciferase reporter construct, and a
plasmid expressing Gaussia luciferase under the control of a
minimal promoter. Dual-luciferase assays were performed, and
the firefly luciferase signals were normalized to the correspond-
ing Gaussia luciferase signals to compensate for differences in
transfection efficiencies and cell numbers. We found that the
O-MRCA Nef suppressed NF-kB activation almost as efficiently
as the control NL4-3 Vpu, whereas contemporary HIV-1 O nef
alleles did not suppress tetherin-mediated NF-kB activation
(Figure 2E). It has previously been reported that M-Nefs enhance
NF-kB activity (Fortin et al., 2004). To determine whether O-Nefs
share this function, we stimulated NF-kB activation by coexpres-
sion of a constitutively active mutant of IKKb in the presence
of Vpu and various Nef proteins. Interestingly, all contemporary
O-Nefs boosted NF-kB activation, whereas the O-MRCA
Nef had no enhancing effect (Figure 2E). Thus, downstream
activating effects of contemporary O-Nefs may mask possible
inhibitory effects on NF-kB activity through downmodulation of
human tetherin.
HIV-1 Group O Nefs Target a Distinct Region in Human
Tetherin
Nef proteins of primate lentiviruses, including those encoded by
SIVcpz and SIVgor, target the precise region of five amino acids
in tetherin that is deleted in the human ortholog (Jia et al., 2009;
Sauter et al., 2009; Zhang et al., 2009). To determine whether O-
Nefs target a different region, we utilized a ‘‘repaired’’ version of
human tetherin (HUM-rep) in which the deleted residues had
been reintroduced (Sauter et al., 2009) and analyzed the effect
of alanine scanning mutations in the cytoplasmic domain on its
susceptibility to SIVgor and HIV-1 O Nef proteins. As expected
(Sauter et al., 2009), alterations in amino acid residues 14–18
(DDIWK) that are missing in human tetherin disrupted its suscep-
tibility to SIVgor Nef (Figure 3). However, these alterations did
not affect the susceptibility of tetherin to O-MRCA or HJ162
Nefs. In contrast, changes in residues 5–8 (SYDY) impaired
the ability of these O-Nefs to downmodulate tetherin (Figure 3).
Analysis of single alanine scanning mutants confirmed that the
YDY residues in human tetherin play a role in downmodulation
by O-Nefs (Figure S3A). Notably, the O-MRCA Nef toleratedMicrobe 16, 639–650, November 12, 2014 ª2014 Elsevier Inc. 641
Figure 2. Functional Analysis of MRCA
HIV-1 Nef Proteins
(A) p24 antigen (left) and infectious virus (right)
release from 293T cells cotransfected with an
HIV-1 NL4-3 DvpuDnef construct and vectors ex-
pressing the NL4-3 Vpu or the O-MRCA Nef and
the indicated amounts of a vector expressing
HUM tetherin. Shown are percentages relative to
those detected in the absence of tetherin (100%).
Values are means from three experiments.
(B) Infectious virus yield from 293T cells co-
transfected with an HIV-1 NL4-3 DvpuDnef
construct and vectors expressing the indicated
nef alleles in combination with plasmids express-
ing HUM or GOR tetherin. Shown are average
values derived from triplicate infections of TZM-bl
indicator cells relative to those obtained in the
absence of tetherin expression vector (100%).
(C) Levels of tetherin cell surface expression in
the presence of HIV-1 group M, N, and O MRCA
Nefs relative to those measured in 293T cells
transfected with the EGFP control vector (100%).
The M-MRCA and M-MRCA P Nefs differ by a
single E to P substitution at their N terminus (Fig-
ure S2A). Values in all panels are means (± SEM)
from at least three experiments.
(D) PHA-activated PBMCs were transduced with
VSV-G-pseudotyped vpu-defective HIV-1 NL4-3
constructs expressing the indicated nef alleles and examined for tetherin surface expression three days later. The results show average levels (± SEM) in virally
infected (EGFP+) cells relative to uninfected cells (100%).
(E) Effect of various Nef and Vpu proteins on NF-kB activation. Activation of NF-kB-dependent firefly luciferase expression in 293T cells cotransfected with
tetherin or constitutively active IKKb, NF-kB-dependent (three NF-kB binding sites) firefly luciferase reporter constructs, a plasmid expressing Gaussia
luciferase under the control of a minimal promoter, and the indicated nef alleles. Shown are average values derived from three experiments (see also
Figure S2).
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HJ162 Nef (Figures 3 and S3A). All mutant forms of tetherin
were efficiently expressed (Figure S3B). These mapping experi-
ments showed that during adaptation to humans HIV-1 O nef al-
leles evolved the capability to target a region in the cytoplasmic
domain of human tetherin that is directly adjacent to the deleted
residues.
Complex Determinants of Group O Nef-Mediated
Antagonism of Human Tetherin
To determine which amino acid changes in Nef conferred the
ability to downmodulate human tetherin, we analyzed a set of
12 chimeras between the active O-MRCA and inactive SIVgor
CP2139 Nefs (Figure 4A). We found that most of these Nef chi-
meras showed functional activities intermediate between the
O-MRCA and SIVgor Nefs. Substitution of the N- and C-terminal
parts of the O-MRCA Nef by those of SIVgor significantly
reduced the effect on cell surface expression of human tetherin
(Figure 4A). Western blot analysis confirmed that these func-
tional differences were not due to different Nef expression levels
(Figure S3A). Analyses of additional chimeras between the HIV-1
O HJ162 or 13127 Nef proteins and the SIVgor Nef confirmed
that residues in the N- and C-terminal region contribute to the
ability of O-Nefs to downmodulate human tetherin (Figure 4B).
Sequence comparison revealed that active and inactive Nefs
differ in at least eight amino acid residues at their C termini (Fig-
ure S4A). Whereas mutation of the C-terminal four of these
residues had no significant effect, mutation of the N-terminal642 Cell Host & Microbe 16, 639–650, November 12, 2014 ª2014 Elsfour residues (K186V, Q188R, S192A, and L195T) significantly
reduced O-MRCA and HJ162 Nef-mediated downmodulation
of human tetherin (Figure 4B). These four residues are in close
proximity of each other and are all exposed at the surface of
Nef (Figure 4C). Thus, they may form a distinct interaction site
with tetherin. However, none of the mutations in HIV-1 O and
SIVgor Nefs fully recapitulated the phenotype of the parental
Nef proteins.
It has been shown that alterations in and near the highly
conserved ExxxLL motif in the C-terminal loop of Nef (Figure 4C)
were critical for the reacquisition of antitetherin activity of a chim-
panzee-adapted HIV-1 strain (Go¨tz et al., 2012). To determine
whether these residuesarealsoessential for theantitetherinactiv-
ity of O-Nefs, we mutated them to the NTS161–163 and VS168/
169 residues found in the inactive NL4-3 Nef (Figure 4D). Func-
tional analyses showed that these amino acid substitutions did
not affect Nef expression levels (Figure S4B), but impaired the
ability of all contemporary HIV-1 ONefs to reduce the cell surface
expression of both human and gorilla tetherin (Figure 4D).
Downmodulation by the O-MRCANef was also reduced by these
changes, albeit less severely and only in the case of human
tetherin. These changes in the variable residues of the otherwise
highly conserved ExxxLL motif (Figure S4C) also disrupted the
modest effect of O-Nefs on virus release in transfected 293T cells
(Figure S4D). In agreement with previous results (Go¨tz et al.,
2012), these alterations in and adjacent to the ExxxLL adaptor
protein interaction site specifically affected tetherin antagonism
and had no significant effect on other Nef functions (Figure 4D,evier Inc.
Figure 3. Mapping of Residues in Human
Tetherin Targeted by HIV-1 O Nefs
Effect of alanine substitutions in the cyto-
plasmic part of HUM-rep tetherin on susceptibility
to SIVgor, O-MRCA, and HJ162 nef alleles. Shown
are the levels of tetherin cell surface expression in
the presence of Nef relative to those measured in
cells transfected with the EGFP-only control vec-
tor (100%). Values are averages (± SEM) derived
from three experiments (see also Figure S3).
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the ability of Nef to counteract tetherin. However, the determi-
nants of Nef-mediated downmodulation of human tetherin seem
to be complex and involve multiple regions in O-Nef proteins.
HIV-1 O Nefs Impair Transport of Human Tetherin to the
Cell Surface
Next, we explored the mechanism of tetherin downmodulation
by HIV-1 O Nefs. It has been reported that SIV Nefs accelerate
endocytosis of monkey or ape tetherins (Zhang et al., 2011;
Serra-Moreno et al., 2013). To determine whether this is also
the case for the effect of O-Nefs on human tetherin, we analyzed
the levels of total and internalized tetherin at different time points
(Figure 5A, left). We found that the O-MRCA and HJ162 Nefs
increased the relative rate of human tetherin internalization after
1 hr from30% to 50% (Figure 5A, right). This effect was disrupted
by the NTSVS mutations in the HJ162 Nef, but not in the O-
MRCA Nef protein. In contrast to Vpu, O-Nefs increased, rather
than reduced, the total intracellular levels of human tetherin. We
did, however, observe a reduction of a low-molecular-weight
form of full-length human tetherin in the presence of the parental
and mutant O-MRCA Nefs (Figure S5A).
The microscopy data and western blot analyses suggested
that O-Nefs may trap human tetherin in intracellular compart-
ments, where it is protected against proteolytic or lysosomal
degradation, but also kept away from the sites of virus budding.
To further examine this possibility, we utilized a plasmid micro-
injection approach that allows monitoring the transport of newly
synthesized protein pools (Schmidt et al., 2011). Constructs
encoding HA-tagged human tetherin and plasmids encoding
EGFP, or AU-1 tagged Vpu or Nef proteins with differing tetherin
downmodulating capacity, were comicroinjected into the nu-
cleus of HT1080 cells that do not express endogenous tetherin.
As expected (Schmidt et al., 2011), newly synthesized tetherin
was rapidly (2 hr) transported to the plasma membrane in
EGFP-expressing control cells, whereas M-Vpu trapped tetherin
in a perinuclear compartment (Figures 5B and 5C). Anterograde
transport of human tetherin was only slightly reduced by the
SIVgor and group M Nef proteins, whereas the O-MRCA and
HJ162 Nefs inhibited it as efficiently as the M-Vpu (Figures 5B
and 5C). At 6 hr postinjection the O-MRCA and HJ162 Nefs
reduced the frequency of cells expressing human tetherin at
their surface from > 90% to < 10% compared to control cells.
In contrast, the O-MRCA-NTSVS and HJ162-NTSVS mutants
achieved only 40%–60% reduction, similar to the control SIVgor
and HIV-1 M Nefs (Figure 5C). Thus, alterations in and near the
ExxxLL motif that impair the tetherin downmodulation activityCell Host &of O-Nefs also reduce their ability to trap human tetherin in a
perinuclear compartment.
Costaining with subcellular markers in cells 2 hr postinjection
identified this compartment as the trans-Golgi network (TGN)
(Figures 5D and S6A), while overlap with markers for early endo-
somes or the ER was not observed (data not shown). Similar
to group M Vpus (Schmidt et al., 2011), O-Nefs induced potent
colocalization of tetherin with the TGN marker TGN46 indicative
of tetherin retention during anterograde transport, and HJ162
Nef even disrupted the organization of the TGN (Figures 5D
and S6A). These effects were not observed when tetherin inter-
action-deficient O-Nefmutants were used. Notably, organization
of the Golgi apparatus was undisturbed in all cases, but O-Nefs
significantly reduced the amounts of tetherin that colocalized
with the Golgi marker GM130 (Figure S6B).
These results suggest that O-Nefs slightly increase human
tetherin internalization, but also impair the anterograde transport
of newly synthesized human tetherin to the cell surface to
retain the restriction factor in the TGN. O-Nefs thus affect teth-
erin anterograde transport at a similar step as M-Vpus, but
may employ different mechanisms to prevent efficient plasma
membrane delivery of the restriction factor.
HIV-1 O Nefs Do Not Antagonize the Short Isoform of
Human Tetherin
Human tetherin is expressed in two isoforms (Cocka and Bates,
2012). The short form is generated by alternative translation initia-
tion fromamethionine residue in thecytoplasmicdomainand lacks
N-terminal serine-threonine and tyrosine motifs, including the re-
gion targetedbyO-Nefs (Figure 6A). This short formwas not signif-
icantly degraded by either M-Vpu or O-Nef proteins (Figure 6B).
Both isoforms of tetherin were expressed at similar levels at the
surface of transfected 293T cells (Figure 6C), and the short isoform
was substantially less sensitive to M-Vpu- and O-Nef-mediated
downregulation than the full-length form (Figure 6D). The modest
effects of O-Nefs on the surface expression of the short isoform
were not affected by the mutations in the C-loop of O-Nefs (Fig-
ure 6D) andmost likely resulted from global effects on cellular traf-
ficking pathways. The envelope glycoprotein of SIV from Tantalus
monkeys (SIVtan) and the NL4-3 Vpu protein, which are known
to target the extracellular (Gupta et al., 2009) and transmembrane
domains of human tetherin, respectively, promoted infectious
virus release in the presence of the short isoform, whereas none
of the O-Nefs displayed significant enhancing effects (Figure 6E).
Thus, in agreement with our finding that O-Nefs target a domain
in the N-terminal region of human tetherin that is missing in the
short isoform, they are only active against the full-length form.Microbe 16, 639–650, November 12, 2014 ª2014 Elsevier Inc. 643
Figure 4. Mapping of Residues in HIV-1
O Nefs Involved in Modulation of Human
Tetherin
(A and B) Effect of chimeras between HIV-1 O and
SIVgor Nefs and mutant O-Nefs on cell surface
expression of HUM tetherin. Alterations intro-
duced into the O-MRCA and HJ162 C1 and C2
mutants are shown in Figure S4A.
(C) Localization of amino acid residues involved in
antitetherin activity in the HIV-1 Nef structure. The
alterations in the C1 region of Nef (red) and the
NTS-x4-VS residues (yellow) in NL4-3 Nef critical
for the tetherin antagonism, the acidic residue and
two leucines (blue) of the dileucine motif involved
in the interaction with AP complexes, and two
conserved amino acids in between (orange), are
highlighted.
(D) Effect of changes in and near the ExxxLL motif
of Nef on downmodulation of HUM or GOR teth-
erin and CD4 cell surface expression. Values
represent average expression levels (± SEM; n = 3)
relative to those obtained in the presence of the
vector expressing only EGFP. Color coding in the
alignment corresponds to that in the Nef structure
shown in (C). See also Figure S4.
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Sensitivity of HIV-1 in Primary T Cells
Although contemporary O-Nefs reduced cell surface expression
of human tetherin, they exerted only very subtle effects on virus
release. To examine this further, we compared the effects of
wild-type (WT) and mutant O-MRCA and HJ162 Nefs on p24 an-
tigen and infectious virus release directly. Western blot analyses
showed that in the absence of an antagonist, even low levels of
tetherin expression reduced p24 release (Figure S7A, EGFP
panel). Reduced levels of p24 release were also observed in the
presence of the NL4-3 and mutant O-MRCA and HJ162 Nefs,
but not in the presence of Vpu and WT O-MRCA and HJ162
Nefs (Figure S7A). Titration experiments confirmed that the O-
MRCA and HJ162 Nefs increased p24 production, and that the
NTSVS mutations disrupted this effect (Figures S7B and S7C).
To examine the effect of O-Nef mutations that abrogated teth-
erin downmodulation on virus release and replication in primary
T cells, we generated vpu-defective proviral NL4-3 constructs
containing WT and mutant HIV-1 O nef alleles. Notably, the cor-
responding HIV-1 clones differed only in the three to five amino
acids in and near the ExxxLL motif that impaired the ability of
O-Nefs to downmodulate human tetherin, but not CD4 and
MHC-I. Infection of P4-CCR5 indicator cells showed that these
mutations did not affect the infectiousness of progeny virions
(Figure 7A). Next, we determined the efficiency of virus release
in the presence and absence of IFNa treatment. We found that
treatment of primary human T cells with IFNa significantly
increased the levels of tetherin surface expression (Figure 7B)
and strongly suppressed the release of HIV-1 particles (Fig-
ure 7C). Strikingly, however, the tetherin downmodulation
function of O-Nefs was associated with levels of p24 release644 Cell Host & Microbe 16, 639–650, November 12, 2014 ª2014 Elsevier Inc.from primary CD4+ T cells that did not
differ significantly from the WT vpu con-
taining HIV-1 construct (Figure 7C). Onaverage, the HIV-1 M-Vpu and O-Nef proteins increased p24
production by about 20% in the absence of, and by 40%–50%
in the presence of, IFNa treatment (Figure 7D). In contrast, the
original NL4-3 M-Nef that is not a tetherin antagonist had no sig-
nificant effect on virus release in the presence and absence of
IFNa, and the mutations in the C-loop of O-Nefs significantly
reduced the enhancing activity (Figure 7D). Finally, we analyzed
whether the tetherin downmodulation function of O-Nefs
affected the sensitivity of HIV-1 replication to inhibition by
IFNa. We found that viruses expressing theWT or NTSVSmutant
O-Nef proteins replicated with near-identical kinetics (Figure 7E)
and produced similar quantities of p24 antigen (Figure 7F) in the
absence of IFNa. In cells pretreated with 500 U/ml IFNa, how-
ever, HIV-1 constructs expressing WT O-Nefs replicated more
effectively and released higher quantities of p24 antigen than
those encoding tetherin-inactive Nef proteins. In comparison,
complete lack of Nef function reduced viral replication in both
the absence and presence of IFNa (Figure 7E). Coinfection
experiments confirmed that viruses expressing WT O-Nefs that
downmodulate human tetherin outcompeted those containing
the mutant nef alleles in IFNa-treated primary T cell cultures
(data not shown). Thus, the antitetherin activity of O-Nefs
promotes virus release (Figure 7F) and counteracts the antiviral
effect of IFNa (Figure 7G) in primary CD4+ T cells.
DISCUSSION
In the present study, we demonstrate that, in contrast to SIVcpz,
SIVgor, and other HIV-1 Nefs, HIV-1 O Nef proteins efficiently
reduce cell surface expression of human tetherin. We further
show that this antitetherin activity depends on a region in the
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cent to the deletion in the human protein. Notably, the Nef protein
of the inferred common ancestor of contemporary HIV-1 groupO
strains targets the same region and is an effective antagonist of
human tetherin. Thus, the activity of Nef against human tetherin
apparently evolved prior to the epidemic spread of HIV-1 group
O. This function was previously missed since the only proviral
group O clone analyzed (CMO2.5) (Yang et al., 2011) encodes
a functionally defective nef allele, and since contemporary
O-Nefs are only poorly active in promoting virus release from
transfected 293T cells (Figure 1A; Sauter et al., 2009; Yang
et al., 2011). In contrast, O-Nefs clearly increased virus release
and enhanced virus resistance to inhibition by IFNa in primary
CD4+ T cells (Figure 7). It is thus tempting to speculate
that Nef-mediated tetherin antagonism facilitated the spread of
groupO viruses in the human population by counteracting innate
immune responses characteristic of acute HIV-1 infection (Par-
rish et al., 2013; Fenton-May et al., 2013).
Several O-Nefs analyzed in the present study have previously
been examined for their antitetherin activity, but only in virus
release assays in transfected 293T cells (Sauter et al., 2009;
Yang et al., 2011). This assay is commonly used because it
allows the testing of restriction factors from different species,
and because M-Vpus show a robust phenotype in this experi-
mental setting. HIV-1 O Nefs enhance virus release in trans-
fected 293T cells only marginally (Figure 1A). However, in
primary CD4+ T cells, the tetherin downmodulation function of
O-Nefs enhanced virus release and reduced the inhibitory effect
of IFNa as efficiently as the M-Vpu protein (Figure 7), although
they were inactive against the short isoform of human tetherin
(Figure 6). Why the antitetherin activity of HIV-1 O Nefs is more
evident in primary CD4+ T cells than in transfected 293T cells
remains to be determined, but one possible explanation is that
contemporary O-Nefs antagonize human tetherin only at physio-
logically relevant, but not at higher, expression levels. Notably,
only the O-MRCA Nef suppressed tetherin-mediated NF-kB
activation and lacked the downstream stimulatory effect on
NF-kB (Figure 2E). Counteraction of human tetherin without
suppression of NF-kB activation by contemporary O-Nefs may
thus reflect advanced adaptation to the human host.
The tetherin downmodulation function of O-Nefs increased the
efficiency of virus release, but enhanced HIV-1 replication only in
CD4+ T cells that were pretreated with IFNa (Figure 7E). Type I
interferon levels are particularly high during acute HIV-1 infec-
tion, which is characterized by a cytokine storm. To counteract
the antiviral effects of this innate immune response, transmitted
founder viruses are significantly more resistant to inhibition by
IFNa than HIV-1 strains that persist during chronic infection (Par-
rish et al., 2013; Fenton-May et al., 2013). Thus, the impact of
Nef-mediated downmodulation of human tetherin may be most
significant during the earliest stages of virus infection.
Evolutionary analyses suggest that HIV-1 group O was trans-
mitted to humans early in the 20th century and thus entered the
human population roughly at the same time as group M viruses
(Lemey et al., 2004). Group O viruses have infected tens of thou-
sands of people, mostly in Cameroon and neighboring countries.
Although groupOprevalence is lower than that of pandemic HIV-
1 group M, it is substantially higher than that of groups N and P,
which have been detected in fewer than 20 individuals. It is thusCell Host &tempting to speculate that the Nef-mediated antitetherin activity
may have facilitated its spread in the human population. Our
finding that this specific O-Nef function reduced the sensitivity
of HIV-1 to inhibition by IFNa is in agreement with this hypothesis
and the previously proposed role of tetherin antagonism in virus
transmission (Gupta and Towers, 2009; Sauter et al., 2010).
However, the effects of O-Nef on viral replication in CD4+ T
lymphocytes (Figure 7E) were weaker than those previously
reported for Vpu (Neil et al., 2007). One potential explanation is
that the mutant O-Nefs may retain some modest antitetherin
activity (Figure 7C). Furthermore, differences in the antitetherin
mechanism and efficacy of O-Nefs and M-Vpus and/or in
the experimental conditions, such as the concentration and
IFN subtypes used, may contribute. In either case, the results
of the present study add to existing evidence that the pandemic,
epidemic, and rare HIV-1 groups have achieved different
degrees of adaptation to the human host. Pandemic group M
strains seem to have cleared the tetherin barrier by evolving
highly efficient Vpu-mediated counteraction of this restriction
factor. Group N strains have evolvedmodest Vpu-mediated anti-
tetherin activity (Sauter et al., 2009; Yang et al., 2010) and are still
in the process of adaptation (Sauter et al., 2012), while group
P-derived Vpu andNef proteins are functionally indistinguishable
from their SIVgor counterparts (Sauter et al., 2011; Yang et al.,
2011). Our finding that HIV-1 O has adapted to humans and
evolved Nef-mediated activity against human tetherin further
illustrates that adaptive processes are highly dynamic, and that
primate lentiviruses utilize multiple avenues to overcome the
restriction factors in a new host.
It has previously been shown that residues in and near the
ExxxLL motif in the C-loop are critical for the interaction of SIV
and chimpanzee-adapted HIV-1 Nefs with the cytoplasmic
domain of tetherin, but not for other Nef functions (Zhang
et al., 2011; Go¨tz et al., 2012; Serra-Moreno et al., 2013). We
found that these residues are also important for the ability of
HIV-1 O Nefs to downmodulate tetherin. They were not respon-
sible, however, for their ability to target a distinct region since
they affected downmodulation of both human and gorilla teth-
erin. The exact alterations that are critical for the ability of O-
Nefs to specifically target human tetherin seem to be complex
and require further investigation. Previous studies suggest that
adaptor protein 2 (AP-2)-dependent endocytosis plays a key
role in Nef-mediated downmodulation of tetherin (Zhang et al.,
2011; Serra-Moreno et al., 2013). Adaptor protein recruitment
seems to be well preserved in O-Nefs since they were fully active
in downmodulating CD4, which depends on AP-2-mediated
endocytosis. Unexpectedly, however, we found that the O-
MRCA and HJ162 Nefs enhanced the rate of internalization of
human tetherin only slightly, but clearly inhibited the transport
of tetherin to the cell surface. Thus, Nef may exploit different
mechanisms to reduce the levels of tetherin at the cell surface.
Recently, it has been shown that HIV-1 Vpu hijacks AP-1-depen-
dent trafficking pathways to counteract tetherin (Jia et al., 2014).
Since AP-1 predominantlymediates vesicular transport from and
to the TGN, this interference likely accounts for the reduction of
tetherin anterograde transport at the level of the TGN. Our results
suggest that O-Nefs may employ a similar mechanism to inter-
fere with transport of tetherin beyond the TGN, which is reminis-
cent to Nef-mediated downmodulation of MHC-I. The observedMicrobe 16, 639–650, November 12, 2014 ª2014 Elsevier Inc. 645
Figure 5. Mechanism of Downmodulation of Human Tetherin by HIV-1 O Nefs
(A) Effects of O-Nefs on cell surface expression and internalization of HUM tetherin. 293T cells were transfectedwith vectors expressing tetherin and the indicated
Nef proteins or only EGFP as control. Cells were stained with antitetherin antibodies, incubated at 37C for different time points, and analyzed by FACS. The left
panel shows the total and intracellular (after acidic wash) MFIs of HUM tetherin expression. The right panel shows the percentage of internalized tetherin in the
presence of the indicated Nef proteins or the absence of Nef. Values represent averages derived from three independent experiments.
(B) Effect of O-Nefs on transport of newly synthesized HUM tetherin to the cell surface. The nuclei of HT1080 cells were comicroinjected with a HUM tetherin
expression plasmid together with vectors encoding EGFP, NL4-3 Vpu, or the indicated Nef proteins. About 200 cells were microinjected and analyzed.
Microphotographs show representative examples. Cell circumferences are indicated by white dashed lines. Scale bar, 10 mM.
(legend continued on next page)
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Figure 6. O-Nefs Do Not Antagonize the Short Isoform of Human Tetherin
(A) Amino acid alignment of the long and short isoforms of HUM tetherin.
(B) Expression of the short form of human tetherin in the presence of Vpu or the indicated Nef proteins. 293T cells were cotransfected with plasmids expressing
the indicated tetherin variants and Vpu or the indicated Nef proteins and examined by western blot 2 days later.
(C) Surface levels of tetherin expression on 293T cells transfected with constructs expressing the long or short isoforms of human tetherin. Results in (C)–(E) show
mean values (± SEM) derived from three to six transfections.
(D) Downmodulation of the two isoforms of human tetherin by the indicated viral proteins. Shown are the levels of cell surface expression relative to those obtained
in the presence of the vector expressing only EGFP.
(E) Virus release from 293T cells cotransfected with an HIV-1 NL4-3 DvpuDnef construct and vectors expressing the indicated viral proteins and a plasmid
expressing the short isoform of HUM tetherin. Virus yield was determined by p24 ELISA (left) and infection of TZM-bl cells (middle). The right panel shows the
correlation between both measurements (see also Figure S6).
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tetherin also suggest, however, that they have evolved a slightly
different molecular mechanism than Vpu to antagonize human
tetherin that will be important to dissect in further studies.
In summary, we show that O-Nefs are antagonists of human
tetherin and target a region in the cytoplasmic domain that is pre-
served in the human ortholog of this restriction factor. Thus, the
five amino acid deletion in the cytoplasmic domain of human
tetherin does not confer complete protection against antago-(C) Histogram bars depict the relative percentage of cells showing the different c
each time point from about 200 cells analyzed.
(D) O-Nefs trap newly synthesized HUM tetherin at the trans-Golgi network (TGN
croinjected as described in (B) that were analyzed for the distribution of the TGNm
tetherin (red) and TGN46 (green) channel. Cell circumferences are indicated by w
Cell Host &nism by primate lentiviral Nef proteins. This has implications for
assessing future zoonotic transmission risks, because tetherin
represents an important species barrier, and the great majority
of primate lentiviruses use Nef to counteract tetherin in their
respective hosts (Sauter et al., 2009; Zhang et al., 2009; Jia
et al., 2009). The fact that primate lentiviruses do not necessarily
have to switch from Nef to other viral factors to antagonize
human tetherin further emphasizes their enormous plasticity to
adapt to new host environments.ategorization (plasma membrane and intracellular versus intracellular only) for
). Shown are representative confocal microphotographs of HT1080 cells mi-
arker 46 at 2 hr postinjection. Depicted are overviews and zoom of the merged
hite dashed lines. Scale bar, 10 mM (see also Figure S5).
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Figure 7. Role of O-Nef-Mediated Downmodulation of HUM Tetherin in HIV-1 Infectivity and Replication Fitness
(A) P4-CCR5 indicator cells were infected with vpu-defective HIV-1 NL4-3 IRES-EGFP constructs containing the indicated nef genes or a defective nef allele.
Infections were performed in triplicate with virus stocks containing 100 ng of p24 antigen. Shown are average values (± SEM) compared to the infectivity of the
nef-defective HIV-1 construct (100%).
(B) Levels of tetherin cell surface expression in uninfected PBMC cultures (n = 3) in the absence and presence of IFNa.
(C) Efficiency of p24 release in CD4+ T cells infected with HIV-1 NL4-3 constructs expressing the indicated nef alleles. Values present percentages of cell-free p24
antigen out of the total p24 detected in the presence and absence of IFNa and were derived from infections of T cells derived from three PBMC donors, each
performed in triplicate. Cell-free and cell-associated p24 antigen was quantified by ELISA at 5 days postinfection. The O nef alleles were examined in the context
of a vpu-defective NL4-3 construct. Constructs expressing the WT NL4-3 nef or containing disrupted vpu and/or nef alleles were examined for control.
(D) Enhancement of p24 release by HIV-1 group M and N accessory proteins. Data were derived from the experiment shown in (A). Shown are mean values (±
SEM; n = 3–9) obtained for the increase of p24 release by the presence of indicated viral genes in the HIV-1 NL4-3 proviral construct compared to the control
construct lacking intact vpu and nef genes.
(E) Virus replication in CD4+ T cells in the presence and absence of IFNa. The replication kinetics of HIV-1 NL4-3 constructs expressing the indicated Nef proteins
are shown in CD4+ T cells from three donors in the absence (upper lines) and presence (lower lines) of 500 U/ml IFNa. Results showmedian values of p24 antigen
production (± SEM; n = 3). Please note that the upper curves overlay one another.
(F) Cumulative p24 antigen release in the culture supernatant over 10 days of viral replication in the absence (left) and presence (right) of IFNa. Shown are mean
values (± SEM) for NL4-3 constructs expressing the O-MRCA and WT O-Nefs (HJ162, HJ428, HJ256) or the respective NTSVS mutant forms.
(G) Ratio of p24 production in the presence and absence of IFNa is plotted for each virus at 5 days postinfection. Symbols are the same as in (B) (see also
Figure S7).
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Generation of MRCA Sequences
Nef MRCA sequences were inferred using both codon and nucleotide evolu-
tionary models as outlined in the Supplemental Experimental Procedures.648 Cell Host & Microbe 16, 639–650, November 12, 2014 ª2014 ElsExpression Vectors
Bicistronic CMV promoter-based pCG expression vectors coexpressing vpu,
nef, CD4, or tetherin and EGFP or DsRed2, respectively, have been described
(Sauter et al., 2009). Splice-overlap extension PCR with primers introducing
XbaI and MluI restriction sites flanking the reading frames was used toevier Inc.
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HIV-1 Group O Nefs Antagonize Human Tetheringenerate chimeric nef alleles as well as tetherin and nef mutants. PCR frag-
ments were purified from agarose gels and inserted into the pCG vector using
standard cloning techniques. All PCR-derived inserts were sequenced to
confirm their accuracy.
Cell Culture and Transfections
239T and TZM-bl cells were cultured and transfected or infected as described
in the Supplemental Experimental Procedures. PBMCs were isolated using
lymphocyte separation medium (Biochrom) and cultured as outlined in the
Supplemental Experimental Procedures.
Flow Cytometric Analysis
To determine the effect of Vpu and Nef on CD4 and tetherin cell sur-
face expression, 293T cells were transfected by the calcium phosphate
method with 1 mg of a CD4 or tetherin expression vector coexpressing
EGFP and 5 mg of pCG EGFP/Vpu or Nef constructs expressing EGFP
alone or together with Vpu or Nef. Two days posttransfection CD4 or teth-
erin expression was examined by FACS analysis as described previously
(Schindler et al., 2006). See Supplemental Experimental Procedures for
details.
Tetherin Antagonism
The capability of Vpu and Nef to antagonize tetherin was determined essen-
tially as described (Sauter et al., 2009). For details, see the Supplemental
Experimental Procedures.
Western Blot
Expression of Vpu, Nef, and tetherin was examined as described in the
Supplemental Experimental Procedures.
Sequence Analyses
Vpu or Nef amino acid sequences were aligned using multiple sequence align-
ment with hierarchical clustering (http://multalin.toulouse.inra.fr/multalin). Vpu
and Nef sequences were drawn from the HIV Sequence Database (http://
www.hiv.lanl.gov/content/index).
Nef Model Building
Structure diagrams based on the SF2 Nef were displayed with PyMOL (http://
www.pymol.org; accession number, 3RBB).
Microscopy
Confocal microscopy was performed using an LSM710 confocal microscope
(Carl Zeiss) as outlined in the Supplemental Experimental Procedures.
Endocytosis Assay
293T cells were transfected with tetherin and Nef expression constructs as
described previously (Go¨tz et al., 2012). Surface tetherin was stained 48 hr
posttransfection, and endocytosis was allowed up to 60 min. Endocytosed
tetherin was measured by FACS. For details, see the Supplemental Experi-
mental Procedures.
Tetherin Anterograde Biosynthetic Transport Assay
HT1080 cells were microinjected and analyzed by confocal microscopy as re-
ported previously (Schmidt et al., 2011). See the Supplemental Experimental
Procedures for details.
Analysis of Viral IFNa Sensitivity
Negatively selected CD4+ T cells were either pretreated with 500 U/ml
IFNa2, or not, for 24 hr and subsequently infected with viral stocks containing
2 ng reverse transcriptase activity. Virus production was monitored by p24
ELISA.
Statistical Analysis
All statistical calculations were performed with a two-tailed unpaired Student’s
t test using GraphPad Prism 5.0. p values < 0.05 were considered significant.
Correlations were calculated with the linear regression module.Cell Host &ACCESSION NUMBERS
The GenBank accession numbers for the group M, O, and N nef MRCA
sequences reported in this paper are KP059118–KP059121.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.chom.2014.10.002.
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